ABSTRACT: Both the American Joint Committee on Cancer (AJCC) and Musculoskeletal Tumor Society (MSTS) staging systems for skeletal sarcomas have major weaknesses. A revised staging system for osteosarcoma (the Vanderbilt system) was developed based on exploratory analyses of the relative prognostic impacts of histologic grade, tumor size, local tumor extension, and specific anatomic sites of metastasis using case records from the National Cancer Database (N ¼ 4,285) . AJCC, MSTS, and Vanderbilt staging schemes were then compared using a separate, population-based cancer registry (the Surveillance, Epidemiology, and End Results database; N ¼ 2,246) as a validation dataset. Predictive accuracy for 5-year sarcoma-specific survival was evaluated by comparing areas under receiver-operating characteristic curves generated from logistic regression. Three different concordance indices and Bayesian information criteria were also calculated for model comparisons. The Vanderbilt staging system showed comparable predictive accuracy for 5-year disease-specific survival (65%) compared to the AJCC (67%) and MSTS (67%) staging systems. Most cross-comparisons of model concordance were not significantly different either. Bayesian information criterion was lowest for the MSTS staging system. Substaging osteosarcoma by current anatomical criteria is ineffectual. A simplified staging system based only on histologic grade and the presence of distant metastasis to any anatomic site performs similarly to the current AJCC and MSTS staging systems by multiple statistical criteria and is proposed for clinical and pathological staging of osteosarcomas of the non-pelvic appendicular and non-spinal axial skeleton. The Musculoskeletal Tumor Society (MSTS) staging system (originally developed by Enneking) also divides Stage I and Stage II by histologic grade, but in contrast to the AJCC system, subclassifies tumors based on local anatomic extension.
The staging algorithm for skeletal sarcomas in the 8th edition of the American Joint Committee on Cancer (AJCC) AJCC Cancer Staging Manual divides lowgrade and high-grade osteosarcomas of the non-pelvic appendicular and non-spinal axial skeleton into Stages I and II, respectively, with substages (i.e., IA and IB; IIA and IIB) defined by dichotomization of tumor size (T1, 8 cm and T2, >8 cm). 1 Low-grade tumors with skip metastasis involving the same bone as the primary neoplasm (T3) are also staged as IB; highgrade T3 tumors are considered Stage III. Stage IV tumors (those with distant metastasis) are subclassified on the basis of lung involvement only (Stage IVA) or involvement of other distant sites, including lymph nodes (Stage IVB).
The Musculoskeletal Tumor Society (MSTS) staging system (originally developed by Enneking) also divides Stage I and Stage II by histologic grade, but in contrast to the AJCC system, subclassifies tumors based on local anatomic extension. 2 Intracompartmental tumors (Stage IA and IIA) are confined by cortical bone, whereas extracompartmental tumors (Stage IB and IIB) extend beyond the cortex. The other major distinction between these two staging schemes is how distant metastasis is staged. All distant metastasis, including skip metastasis, is considered Stage III in the MSTS system.
Both systems have disadvantages. Dichotomization of a continuous variable, such as size in the AJCC system, is imprudent and poor statistical practice. [3] [4] [5] Prior evidence and more recent data demonstrate that hazard ratios associated with tumor size are log-linear-and cannot be modeled effectively in binary format. 6, 7 Assessing local tumor extent in terms of regional anatomic boundaries might be preferable. But substaging osteosarcomas based on extracortical extension classifies approximately 70% of high-grade tumors as Stage IIB, which is suboptimal for risk stratification of individual patients. 8 Moreover, the potential prognostic information provided by site of metastasis in the AJCC system is not utilized in the MSTS system, in which all metastatic sites (including skip metastasis) are considered Stage III.
Which method is optimal for staging osteosarcoma remains unclarified. Although a prior study comparing the AJCC and MSTS staging systems disclosed no significant differences in prognostic performance or concordance with outcomes, this study was underpowered. 8 Using data from a large, multi-institutional cancer registry (the National Cancer Database), a novel staging system (the Vanderbilt system) for osteosarcoma was developed based on exploratory analyses of the relative prognostic impacts of histologic grade, tumor size, degree of local tumor extension, and sites of metastatic disease on overall survival. Predictive accuracy for 5-year sarcoma-specific survival and concordance with clinical outcomes of the AJCC, MSTS, and Vanderbilt staging schemes were directly compared in a retrospective cohort study using a separate cancer registry (the Surveillance, Epidemiology, and End Results [SEER] Program) as a validation dataset to determine which staging system is optimal for staging osteosarcoma of the non-pelvic appendicular and non-spinal axial skeleton.
METHODS
Training Dataset-The National Cancer Database Osteosarcoma Cohort The National Cancer Database, established in 1989 as a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society, is a nationwide, facility-based, comprehensive clinical surveillance resource oncology dataset that currently captures 70% of all newly diagnosed malignancies in the US annually. 9 The data used in this study are derived from a de-identified National Cancer Database file. The American College of Surgeons has executed a Business Associate Agreement that includes a data use agreement with each of its Commission on Canceraccredited hospitals. The Commission on Cancer's National Cancer Database and participating hospitals are the source of the de-identified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the author. Neither has the American College of Surgeons verified the analytic or statistical methodology employed; they are also not responsible for the conclusions drawn from these data by the investigator. Study materials may be obtained from the American College of Surgeons' Commission on Cancer only by investigators at Commission on Cancer-accredited facilities.
The National Cancer Database (Participant User File 2014) was queried for all subtypes of skeletal osteosarcoma. Of the initial 7,708 cases identified, 989 involved sites no longer staged by size alone in the 8th edition of the AJCC staging system (pelvis, sacrum, or coccyx; N ¼ 797; vertebral column; N ¼ 192). Site of origin was not specified for another 191 cases; these cases were excluded from further analysis. Also excluded were cases for which surgical resection was not performed or could not be confirmed (N ¼ 849), critical staging criteria were missing (N ¼ 677), no clinical follow-up was available (N ¼ 628; 98% of which were diagnosed in 2014), and for which the diagnosis was not confirmed by Validation Dataset-The Surveillance, Epidemiology, and End Results Osteosarcoma Cohort For this retrospective population-based study (Level of Evidence III), the SEER database was queried for all skeletal sarcomas or malignant bone tumors from all anatomic sites (see Appendix for SEER Ã Stat version used, database queried, and search criteria). Of the initial 28,317 cases identified, 10,568 were of extra-osseous origin and 10,891 were not osteosarcoma; these cases were excluded. Also excluded were cases diagnosed prior to 1988 (N ¼ 803), those without confirmed surgical resection (N ¼ 1,688), or with unknown vital status (N ¼ 444). Skeletal sarcomas of pelvis, sacrum, or spine, along with cases of unknown anatomic site (N ¼ 306) were also excluded. Critical anatomic staging information (tumor size, local extent, or distant metastasis) was unavailable for an additional 1,371 cases. The final cohort consisted of 2,246 cases diagnosed between 1988 and 2013.
Variables downloaded included information on patient age, sex, year of diagnosis, anatomic site, histologic grade, tumor size, lymph node and/or distant metastasis at diagnosis, disease-specific survival status, and follow-up interval. Information on regional tumor extent was extracted from the SEER database using the Collaborative Stage extension and EOD 10-extent (1988-2003) variables. 10, 11 The Institutional Research Board at Vanderbilt University Medical Center approved the study protocol and provided a waiver of informed consent.
Statistical Methods
The relative impact of various potential staging criteria was assessed using nomographic techniques. 12 Optimal cut-offs of tumor size for predicting the presence of extraperiosteal tumor extension were derived from nonparametric receiveroperating characteristic (ROC) curve analysis using the definitions of Liu and Youden, as well as the nearest method (point on ROC curve closest to [0,1]). [13] [14] [15] Optimal cut-off points for substaging non-metastatic osteosarcoma on the basis of histologic grade and tumor size were also determined using classification and regression tree (CART) analysis for failure time data. [16] [17] [18] Several different statistical methods were applied in the assessment of different staging systems for osteosarcoma. First, Kaplan-Meier sarcoma-specific survival curves were plotted and compared visually. Next, the predictive accuracy of each staging system for determining 5-year sarcoma-specific survival was evaluated by comparing the areas under receiver-operating characteristic (ROC) curves generated from logistic regression analysis. Three different concordance indices (Harrell's c, Somers' D, and G€ onen and Heller's K) were calculated for model comparisons.
19-21 Since Harrell's c and Somers' D neglect censored outcomes that occur before events, this potential source of bias was minimized by excluding 627 patients censored before 5-years of clinical follow-up and by comparing the differences of the estimated indices between nested regression models. These statistics were computed via bootstrap techniques (500 replications) on separate training and validation sets semi-randomly created after sorting on each staging system to ensure relatively similar percentages of each tumor stage in the bootstrapped samples.
The amount of variation in observed outcomes explained by the various regression models was assessed using O'Quigley's r 2 k and Royston's modification thereof (R   2   ) . 22, 23 Standard errors for these estimates were calculated using bootstrap techniques with 500 replications. Finally, Bayesian information criteria (based on the number of deaths, and not simply overall sample size) were also calculated for each staging system as measures of model fit. 24, 25 All results are from 2-sided hypothesis tests using a ¼ 0.05. All analyses were performed using Stata v13.1 (Stata Corp., College Station, TX).
RESULTS
The National Cancer Database Osteosarcoma Cohort Clinicopathologic characteristics of the National Cancer Database cohort of patients with osteosarcoma are available in Table S1 . Mean age of the patients was 29 years (SD, 20 years; median, 20 years; interquartile range, 14-41 years). Tumor size averaged 9 cm (SD, 5 cm; median, 8 cm; interquartile range, 6-12 cm). Median follow-up for censored patients was 59 months (range, <1-143 months). 1,400 (33%) patients died a median of 23 months after diagnosis (range, <1-129 months).
Tumor Size as a Prognostic Marker in Osteosarcoma
The greatest dimension of an osteosarcoma is considered an important prognostic factor. It certainly is OSTEOSARCOMA STAGING when analyzed as a continuous variable, 7 because the 3-5% increase in risk for every 1 cm increase in tumor size translates into a sevenfold increase in risk of death over the range of tumor sizes observed in this cohort. However, when tumor size is dichotomized into a binary variable ( 8 vs. >8 cm, as in the AJCC staging system) this prognostic information is lost. Since the true hazard for tumors slightly greater than 8 cm in size is not considerably different for tumors slightly less than 8 cm, substaging patients with tumors 6-10 cm in size (approximately 40% of cases in this cohort) is meaningless. This loss of information is illustrated further by comparing the effects of tumor size as a continuous variable or a binary variable in nomograms (Fig. S1) . This is the crux of the problem incurred when dichotomizing a continuous variable.
Nevertheless, CART analysis was performed to identify statistically optimal size cut-off points for predicting overall survival. These results suggested size cut-offs of 12 cm for low-and intermediate-grade tumors and 10.5 cm for high-grade tumors. However, a staging system based on these recommended sizecutoffs was not significantly different from either the AJCC or MSTS staging systems (data not shown).
Local Tumor Extension as a Prognostic Marker in Osteosarcoma
Local tumor extension was next assessed as a possible staging criterion (Fig. S2) . After controlling for patient age, histologic grade, and the presence of metastasis, tumors extending beyond the periosteum were associated with significantly higher risk of death than tumors confined to the periosteum (hazard ratio 1.6 [95%CI 1.3-2.0]; P < 0.0005). In contrast, tumors limited to the cortex and extracortical tumors confined by the overlying periosteum showed no significant differences in overall survival (hazard ratio 1.0 [95%CI 0.8-1.3]; P ¼ 0.93). Indeed, results from a previous analysis showed that a staging system based on extraperiosteal extension (instead of extracortical extension, as used in the MSTS system) was statistically significantly better than both the AJCC and MSTS staging systems (Cates, 7 unpublished data). However, since the presence of extraperiosteal tumor extension cannot be reliably determined before surgical resection and gross and histopathologic examination, this staging system cannot be used for clinical staging in the pre-operative setting.
To determine whether tumor size could be used as a surrogate marker for the presence of periosteal transgression, ROC curves were analyzed to determine optimal cut-off values of tumor size for predicting for extraperiosteal extension. Unfortunately, the optimal cut-off size was calculated to be 8 cm, the cut-off point already used in the AJCC staging system. Interestingly, the presence of extraperiosteal extension seems to account for almost all the prognostic information encoded by tumor size dichotomized at 8 cm (Fig. S3) .
Histologic Grade and Site of Metastasis as Prognostic Markers
While the AJCC and MSTS systems consider intermediate-grade osteosarcomas as high-grade for staging purposes, analysis of histologic grade after controlling for patient age, tumor size, and presence of metastasis confirmed that intermediate-grade tumors behaved more like low-grade tumors than high-grade tumors in this series (Fig. S4) . The AJCC also substages osteosarcoma based on site(s) of metastatic involvement. However, after controlling for patient age, histologic grade, and tumor size, there are no significant differences in overall survival based on site of metastasis ( Fig. S5 and Table S2 ). Since there were only 20 cases with isolated lymph node metastasis, the risk associated with this site of metastasis is difficult to estimate. However, it does not appear to be significantly different from that of other sites.
Development of the Vanderbilt Staging System for Osteosarcoma
A nomogram for overall survival of patients with osteosarcoma in the National Cancer Database was constructed as an initial step in developing an alternative staging system for osteosarcoma (Fig. 1) . The nomogram, together with the results of the above exploratory analyses, suggest that dichotomized tumor size and radiographically detectable local tumor extent (intracortical vs. extracortical extension) contribute relatively little prognostic information to the predictive model and have only a minor impact on risk stratification. Conversely, histologic grade and presence of metastatic disease were strong prognostic factors. Therefore, since classification of prognosis by alterative categorizations of tumor size or local tumor extension failed to improve the staging system for osteosarcoma, these variables were abandoned as critical anatomic staging factors. Instead, a new, simplified staging algorithm for osteosarcoma was derived based on histologic grade and presence of metastatic disease alone (Table 1) .
Cases were grouped according to histologic grade and sites of distant metastasis and stage groupings were assigned based on visual assessments of KaplanMeier survival curves and calculated overall survival rates ( Fig. S6 and Table S3 ). Given the limited number of low and intermediate-grade osteosarcomas associated with metastasis, definitive conclusions regarding the level of risk for these groups cannot be made from this data. Low-and intermediate-grade tumors associated with skip metastasis only (N ¼ 6) were considered non-metastatic, while the presence of lymph node (N ¼ 0), lung (N ¼ 7), or other distant metastasis (N ¼ 0) was staged as for high-grade tumors.
The Surveillance, Epidemiology, and End Results Osteosarcoma Cohort Clinicopathologic characteristics of the SEER cohort of patients with osteosarcoma are provided in Table S4 . 
Comparison of AJCC, MSTS, and Vanderbilt Systems for Staging Osteosarcoma
The AJCC, MSTS, and Vanderbilt staging systems were compared to determine which, if any, is most predictive of patient outcome. Visual inspection of Kaplan-Meier plots for sarcoma-specific survival showed poor discrimination between several substages of both the AJCC and MSTS staging systems (Fig. 2) . Note in particular the minimal contrast observed between AJCC stages separated by dichotomization of tumor size (Stages IA and IB and Stages IIA and IIB) and site of metastasis (Stages III, IVA, and IVB). In contrast, the discriminatory ability of the Vanderbilt system is clearly superior to both other staging systems.
Predictive Ability for 5-Year Sarcoma-Specific Survival
The capacity for each staging system to predict 5-year sarcoma-specific survival was assessed by logistic regression using the subset of cases not censored before 5 years of follow-up. In this subset (N ¼ 1,619), 1,027 patients survived at least 5 years after diagnosis and 592 (37%) died of osteosarcoma within 5 years of initial diagnosis. ROC curves generated from logistic regression models (Fig. 3) failed to reveal clinically significant differences in the predictive abilities of the examined staging systems (AJCC, 67% [SE 1%]; MSTS, 67% [SE 1%]; Vanderbilt system, 65% [SE 1%]).
Comparison of Concordance Indices and Measures of Model Fit
G€ onen & Heller's K and Somers' D indices were similar for each staging system, without statistically significant differences (Table 2) . Post-hoc tests for Harrell's c demonstrated that concordance for the MSTS system was significantly greater than the Vanderbilt system (P ¼ 0.01); other comparisons were not significantly different. Measures of degree of ) explained by the regression models were not significantly different either. Bayesian information criterion was lowest for the MSTS staging system, suggesting that this staging system provides the best fitting regression model.
DISCUSSION
The AJCC staging system for osteosarcoma is flawed. As demonstrated previously and further illustrated here, substaging osteosarcoma based on dichotomized tumor size is pointless. 7 Moreover, substaging patients with metastatic disease based on specific anatomic sites of involvement also contributes little prognostic information. Although the MSTS staging system avoids these particular staging problems, substaging osteosarcoma based on extracortical extension does not discern a meaningful increase in level of risk either. The only strong, independent prognostic factors available for clinical staging osteosarcoma prior to surgical resection are histologic grade and the presence of metastasis (to any distant site). Thus, the Vanderbilt staging system for osteosarcoma was developed using only these two variables.
The discriminatory ability, predictive accuracy, extent of explained variation, and various concordance indices for these three staging systems were evaluated using a large population-based cancer registry. Each of these analyses showed that the simplified Vanderbilt staging system performs similarly to the more complicated AJCC and MSTS systems. Few other analytical comparisons of various staging schemes for skeletal sarcoma have been reported. In one previous study, the AJCC and MSTS staging systems performed comparably. 8 Similar results were observed in the larger cohort studied here.
A particular advantage of the Vanderbilt system compared to the AJCC and MSTS systems is its simplicity. Weak or irrelevant staging criteria are not considered. That tumor size dichotomized at 8 cm contributes little to a prognostic model should be intuitive, since the log-hazard for tumor size is linear. Dichotomizing tumor size at its approximate median value therefore results in a large proportion of cases being arbitrarily assigned different levels of risk when 
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CATES in fact no significant difference in risk exists. 7 This is a major disadvantage in converting an intrinsically continuous prognostic parameter into a binary variable. Additional critiques of the 8 th edition of the AJCC system have been recently published. 8 It also should be noted that the AJCC committee on skeletal sarcomas has excluded pelvic and spinal sarcomas from the current staging algorithm; ironically, skeletal sarcomas at these anatomic sites are now assigned T categories based on local tumor extension.
The main problem with the MSTS staging system is considering the cortex of the involved bone, and not the periosteum, as the pertinent anatomic landmark by which to substage osteosarcoma. Extraperiosteal extension is associated with significantly greater risk of death than tumor extension beyond the cortex with lifting of, but not invasion through the overlying periosteum. Although a staging system based on local tumor extent (extension beyond periosteum) performed better than both the AJCC and MSTS systems statistically (Cates, 7 unpublished data), the degree of improvement was of marginal clinical significance. Moreover, since periosteal transgression cannot be reliably determined radiographically, this staging system cannot be used in the pre-surgical setting. Regardless, local tumor extent should be carefully noted and recorded in pathology reports of osteosarcoma resection specimens, as recommended in the Collaborative Stage Data Collection System. 10 Several other factors besides tumor stage (such as histologic response to neoadjuvant chemotherapy, surgical resection margin status, and anatomic location [distal appendicular vs. proximal appendicular]) seem predictive of clinical outcome in osteosarcoma. [26] [27] [28] [29] [30] [31] However, other than anatomic location, this information is not available pre-operatively and is not helpful for clinical or pre-surgical staging. Therefore, these factors were not considered in the development of the Vanderbilt staging system.
Case records from the SEER Program of the National Cancer Institute, a population-based cancer registry representing approximately 28% of the US population, were used to validate the Vanderbilt staging system and directly compare its performance with the AJCC and MSTS staging systems. Advantages of using this database for clinical study include its large sample size, documentation of tumor stage at diagnosis, and availability of cause-specific mortality data provided by the National Center for Health Statistics. However, there are some problems with this database, such as the lack of central review by expert subspecialist pathologists and incomplete or missing data for many records, particularly older cases.
Only osteosarcoma patients were analyzed here, since osteosarcoma is the most common primary sarcoma of bone. Whether the Vanderbilt staging system performs as well or better than the AJCC and MSTS staging systems for the other common primary skeletal sarcomas will require additional study. In summary, a newly developed staging system for osteosarcomas of the non-pelvic appendicular and nonspinal axial skeleton based solely on histologic grade and presence of metastatic disease is proposed. The Vanderbilt staging system performs similarly to the current AJCC and MSTS staging systems. The AJCC should reconsider risk stratification of skeletal sarcomas based on dichotomized tumor size.
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